Saturday 17 October 2026
Export PETS’s income statement to Excel — free account
PetMed Express, Inc.
PETS Healthcare Pharmaceutical Retailers
PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025. In the quarter to June 2026, revenue fell 19.9%, EPS grew 83.0% and free cash flow grew 38.6%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
1.20
0.02
−1.64%
Follow PETS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.25 | 0.27 | 0.36 | 0.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.42) | (10.05) | (7.30) | (24.12) | |
P/B ratio |
1.81 | 1.65 | 2.05 | 1.22 | |
Price to Tangible BV |
3.35 | 2.63 | 3.13 | 1.68 | |
EV/Sales |
0.17 | 0.15 | 0.22 | 0.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.20) | (0.93) | (2.42) | (1.90) | |
EV/FCF |
(1.03) | (0.80) | (1.76) | (1.04) | |
Quick Ratio |
0.36 | 0.45 | 0.52 | 0.67 | |
Current Ratio |
0.68 | 0.84 | 0.89 | 1.05 | |
Net Debt/EBITDA |
3.20 | (0.89) | 3.34 | 1.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.95 | 1.56 | 1.61 | 1.61 | |
Operating CF/Net income |
1.25 | 1.17 | 0.87 | 0.26 | |
Capex/Depreciation |
(0.30) | (0.02) | 0.01 | 0.11 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
37.59% | 40.19% | 43.10% | 41.74% | |
Intangible Assets out of Total Assets |
0.17 | 0.13 | 0.13 | 0.12 | |
Share Based Compensation of Revenue |
0.48% | 0.64% | 0.62% | 0.56% | |
Graham Net Nets |
(0.32) | (0.18) | (0.10) | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(71.88%) | (120.61%) | (97.50%) | (105.58%) | |
Free Cash Flow Yield |
(66.72%) | (69.20%) | (34.09%) | (29.91%) | |
Revenue per Share |
1.89 | 2.05 | 1.94 | 2.12 | |
Operating CF per Share |
(0.35) | (0.23) | (0.44) | (0.10) | |
Capex per Share |
(0.03) | (0.03) | 0.00 | (0.13) | |
Free Cash Flow per Share |
(0.38) | (0.26) | (0.44) | (0.23) | |
Cash per Share |
0.60 | 1.02 | 1.28 | 1.73 | |
Shareholders Equity per Share |
1.06 | 1.38 | 1.56 | 2.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.06 | 1.38 | 1.56 | 2.06 | |
Free Cash Flow |
(8.33) | (5.46) | (9.18) | (4.80) | |
Working Capital |
(12.99) | (8.47) | (6.26) | 2.77 | |
Capital Expenditures |
(0.64) | (0.72) | 0.02 | (2.62) | |
Net Current Asset Value |
(13.17) | (8.69) | (6.69) | 2.22 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.00 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.66 | 2.11 | 1.91 | 1.79 | |
Average Payables |
16.17 | 22.24 | 15.62 | 18.04 | |
Average Inventory |
13.41 | 14.91 | 12.00 | 13.93 | |
Average Assets |
86.80 | 114.95 | 116.38 | 123.17 | |
Average Common Equity |
37.26 | 57.03 | 64.47 | 69.74 |
Columns are period end dates